IMCR vs. ACLX, SWTX, TWST, DNLI, VCEL, KYMR, CGON, APGE, SANA, and IOVA
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Vericel (VCEL), Kymera Therapeutics (KYMR), CG Oncology (CGON), Apogee Therapeutics (APGE), Sana Biotechnology (SANA), and Iovance Biotherapeutics (IOVA). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.
Arcellx has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
96.0% of Arcellx shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 6.2% of Arcellx shares are held by insiders. Comparatively, 9.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Arcellx currently has a consensus target price of $78.73, indicating a potential upside of 52.22%. Immunocore has a consensus target price of $81.85, indicating a potential upside of 46.13%. Given Immunocore's stronger consensus rating and higher probable upside, analysts plainly believe Arcellx is more favorable than Immunocore.
Immunocore has a net margin of -22.60% compared to Immunocore's net margin of -38.39%. Immunocore's return on equity of -13.11% beat Arcellx's return on equity.
Immunocore received 3 more outperform votes than Arcellx when rated by MarketBeat users. However, 76.27% of users gave Arcellx an outperform vote while only 70.59% of users gave Immunocore an outperform vote.
Immunocore has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunocore had 2 more articles in the media than Arcellx. MarketBeat recorded 34 mentions for Immunocore and 32 mentions for Arcellx. Immunocore's average media sentiment score of 0.54 beat Arcellx's score of 0.07 indicating that Arcellx is being referred to more favorably in the media.
Summary
Arcellx beats Immunocore on 9 of the 17 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
